157 related articles for article (PubMed ID: 22807641)
1. Effects of pitavastatin on plasminogen activator inhibitor-1 in hyperlipidemic patients.
Nomura S; Taniura T; Shouzu A; Omoto S; Inami N; Fujita S; Tamaki T; Yokoi T; Shimizu T; Ito T
Int J Gen Med; 2012; 5():535-40. PubMed ID: 22807641
[TBL] [Abstract][Full Text] [Related]
2. Effects of pitavastatin on monocyte chemoattractant protein-1 in hyperlipidemic patients.
Nomura S; Shouzu A; Omoto S; Inami N; Shimazu T; Satoh D; Kajiura T; Yamada K; Urase F; Maeda Y; Iwasaka T
Blood Coagul Fibrinolysis; 2009 Sep; 20(6):440-7. PubMed ID: 19525846
[TBL] [Abstract][Full Text] [Related]
3. Effects of miglitol in platelet-derived microparticle, adiponectin, and selectin level in patients with type 2 diabetes mellitus.
Nomura S; Omoto S; Yokoi T; Fujita S; Ozasa R; Eguchi N; Shouzu A
Int J Gen Med; 2011; 4():539-45. PubMed ID: 21845063
[TBL] [Abstract][Full Text] [Related]
4. The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients.
Nomura S; Inami N; Shouzu A; Omoto S; Kimura Y; Takahashi N; Tanaka A; Urase F; Maeda Y; Ohtani H; Iwasaka T
Platelets; 2009 Feb; 20(1):16-22. PubMed ID: 19172517
[TBL] [Abstract][Full Text] [Related]
5. Correlation between adiponectin and reduction of cell adhesion molecules after pitavastatin treatment in hyperlipidemic patients with type 2 diabetes mellitus.
Nomura S; Shouzu A; Omoto S; Inami N; Tanaka A; Nanba M; Shouda Y; Takahashi N; Kimura Y; Iwasaka T
Thromb Res; 2008; 122(1):39-45. PubMed ID: 17920663
[TBL] [Abstract][Full Text] [Related]
6. Effect of acarbose on platelet-derived microparticles, soluble selectins, and adiponectin in diabetic patients.
Shimazu T; Inami N; Satoh D; Kajiura T; Yamada K; Iwasaka T; Nomura S
J Thromb Thrombolysis; 2009 Nov; 28(4):429-35. PubMed ID: 19137265
[TBL] [Abstract][Full Text] [Related]
7. Effects of pitavastatin on adiponectin in patients with hyperlipidemia.
Inami N; Nomura S; Shouzu A; Omoto S; Kimura Y; Takahashi N; Tanaka A; Nanba M; Shouda Y; Iwasaka T
Pathophysiol Haemost Thromb; 2007; 36(1):1-8. PubMed ID: 18332608
[TBL] [Abstract][Full Text] [Related]
8. Effects of teneligliptin on PDMPs and PAI-1 in patients with diabetes on hemodialysis.
Okuda Y; Omoto S; Taniura T; Shouzu A; Nomura S
Int J Gen Med; 2016; 9():65-71. PubMed ID: 27110135
[TBL] [Abstract][Full Text] [Related]
9. Correlation and association between plasma platelet-, monocyte- and endothelial cell-derived microparticles in hypertensive patients with type 2 diabetes mellitus.
Nomura S; Inami N; Shouzu A; Urase F; Maeda Y
Platelets; 2009 Sep; 20(6):406-14. PubMed ID: 19658004
[TBL] [Abstract][Full Text] [Related]
10. Adiponectin diminishes platelet aggregation and sCD40L release. Potential role in the metabolic syndrome.
Restituto P; Colina I; Varo JJ; Varo N
Am J Physiol Endocrinol Metab; 2010 May; 298(5):E1072-7. PubMed ID: 20197504
[TBL] [Abstract][Full Text] [Related]
11. Activated platelet and oxidized LDL induce endothelial membrane vesiculation: clinical significance of endothelial cell-derived microparticles in patients with type 2 diabetes.
Nomura S; Shouzu A; Omoto S; Nishikawa M; Iwasaka T; Fukuhara S
Clin Appl Thromb Hemost; 2004 Jul; 10(3):205-15. PubMed ID: 15247977
[TBL] [Abstract][Full Text] [Related]
12. Effects of sarpogrelate, eicosapentaenoic acid and pitavastatin on arterioslcerosis obliterans-related biomarkers in patients with type 2 diabetes (SAREPITASO study).
Nomura S; Taniura T; Shouzu A; Omoto S; Suzuki M; Okuda Y; Ito T
Vasc Health Risk Manag; 2018; 14():225-232. PubMed ID: 30271161
[TBL] [Abstract][Full Text] [Related]
13. Simvastatin reduces circulating plasminogen activator inhibitor 1 activity in volunteers with the metabolic syndrome.
Wang L; Rockwood J; Zak D; Devaraj S; Jialal I
Metab Syndr Relat Disord; 2008 Jun; 6(2):149-52. PubMed ID: 18484901
[TBL] [Abstract][Full Text] [Related]
14. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
Yener S; Comlekci A; Akinci B; Demir T; Yuksel F; Ozcan MA; Bayraktar F; Yesil S
Med Princ Pract; 2009; 18(4):266-71. PubMed ID: 19494532
[TBL] [Abstract][Full Text] [Related]
15. Soluble CD40 ligand, platelet surface CD40 ligand, and total platelet CD40 ligand in atrial fibrillation: relationship to soluble P-selectin, stroke risk factors, and risk factor intervention.
Choudhury A; Chung I; Panja N; Patel J; Lip GYH
Chest; 2008 Sep; 134(3):574-581. PubMed ID: 18641098
[TBL] [Abstract][Full Text] [Related]
16. Increased plasma levels of soluble CD40 ligand correlate with platelet activation markers and underline the need for standardized pre-analytical conditions.
Riondino S; Martini F; La Farina F; Spila A; Guadagni F; Ferroni P
Clin Biochem; 2010 May; 43(7-8):666-70. PubMed ID: 20060822
[TBL] [Abstract][Full Text] [Related]
17. Adiponectin is inversely related to plasminogen activator inhibitor type 1 in patients with stable exertional angina.
Maruyoshi H; Kojima S; Funahashi T; Miyamoto S; Hokamaki J; Soejima H; Sakamoto T; Kawano H; Yoshimura M; Kitagawa A; Matsuzawa Y; Ogawa H
Thromb Haemost; 2004 May; 91(5):1026-30. PubMed ID: 15116265
[TBL] [Abstract][Full Text] [Related]
18. Could changes in adiponectin drive the effect of statins on the risk of new-onset diabetes? The case of pitavastatin.
Arnaboldi L; Corsini A
Atheroscler Suppl; 2015 Jan; 16():1-27. PubMed ID: 25575403
[TBL] [Abstract][Full Text] [Related]
19. Plasma TAFI and soluble CD40 ligand do not predict reperfusion following thrombolysis for acute myocardial infarction.
Cruden NL; Graham C; Harding SA; Ludlam CA; Fox KA; Newby DE
Thromb Res; 2006; 118(2):189-97. PubMed ID: 16055173
[TBL] [Abstract][Full Text] [Related]
20. [sCD40L, sP-selectin and sICAM-1 plasma levels in nasopharyngeal carcinoma].
Li L; Li P; Yang YQ; Zhang H; Ai P; Wang F; Jiang Y; Zou LQ; Yan X; Luo F
Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 May; 40(3):513-6. PubMed ID: 19627017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
